Posted by Michael Wonder on 13 Nov 2021
NICE does not recommend elosulfase alfa for NHS use following evaluation of new evidence
12 November 2021 - NICE has today published draft guidance for public consultation which does not recommend elosulfase alfa (also called Vimizin and made by BioMarin) for the treatment of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome).
Today’s draft guidance follows an evaluation of new evidence on the use of elosulfase alfa through research and the collection of ‘real-world’ data as part of a managed access agreement which has made the treatment available on the NHS since 2015.
